1 / 1

Pacritinib(Vonjo)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

BIOVITRUM AB

Formulation:

CAPSULE

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Vonjo(Pacritinib) Instructions:Uses,Dosage, Side Effects

VONJO (pacritinib) is a prescription kinase inhibitor supplied as 100 mg capsules. It is characterized by its distinct mechanism of action, which selectively targets key kinases like JAK2, FLT3, and IRAK1 without inhibiting JAK1. This profile positions it as a specialized therapeutic option for managing myelofibrosis in adults presenting with significant thrombocytopenia, a condition where treatment choices are often limited.

Generic name

Pacritinib(Vonjo)

English name

Pacritinib

Alternative Names

Vonjo

Drug prices

Indications

VONJO is indicated for the treatment of adult patients with intermediate or high-risk primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia) who have a baseline platelet count below 50 × 10⁹/L. This approval was granted under an accelerated pathway based on the endpoint of spleen volume reduction.

Therapeutic Target

JAK2,mutant JAK2V617F,FLT3,IRAK1,ACVR1/ALK2.CSF1R

Active Ingredients

Pacritinib citrate.

Dosage form

CAPSULE

specifications

100mg * 120 capsules/box

Description

Dosage and Administration

The standard dosage is 200 mg (two 100 mg capsules) taken orally twice daily.

CATEGORY NAVIGATION